Press coverage about Abaxis (NASDAQ:ABAX) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abaxis earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.0101157590516 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Abaxis (ABAX) opened at $68.65 on Friday. The stock has a market capitalization of $1,519.63, a PE ratio of 63.56, a P/E/G ratio of 11.00 and a beta of 1.26. Abaxis has a 12 month low of $43.66 and a 12 month high of $78.53.
Abaxis (NASDAQ:ABAX) last posted its earnings results on Thursday, January 25th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.05. The company had revenue of $59.70 million for the quarter, compared to analysts’ expectations of $59.37 million. Abaxis had a return on equity of 10.09% and a net margin of 10.51%. Abaxis’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.30 earnings per share. equities analysts anticipate that Abaxis will post 1.2 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, March 1st will be paid a $0.16 dividend. The ex-dividend date is Wednesday, February 28th. This represents a $0.64 annualized dividend and a dividend yield of 0.93%. Abaxis’s payout ratio is presently 59.26%.
Several research analysts have recently commented on the company. Bank of America lifted their price objective on Abaxis from $46.00 to $48.00 and gave the stock a “sell” rating in a report on Thursday, February 8th. Zacks Investment Research downgraded Abaxis from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. BidaskClub upgraded Abaxis from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. Canaccord Genuity reiterated a “hold” rating and issued a $65.00 price objective on shares of Abaxis in a report on Monday, January 29th. Finally, Stifel Nicolaus lifted their price objective on Abaxis from $48.00 to $57.00 and gave the stock a “hold” rating in a report on Friday, January 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company’s stock. Abaxis currently has an average rating of “Hold” and an average target price of $62.30.
In related news, VP Craig Tockman sold 1,650 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $74.33, for a total value of $122,644.50. Following the sale, the vice president now directly owns 10,866 shares of the company’s stock, valued at $807,669.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Prithipal Singh sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $74.63, for a total value of $149,260.00. Following the completion of the sale, the director now directly owns 44,000 shares in the company, valued at $3,283,720. The disclosure for this sale can be found here. 4.30% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This report was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://transcriptdaily.com/2018/02/25/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-abaxis-abax-share-price.html.
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.